Atherosclerosis and Cardiovascular Disease

Atherosclerosis and Cardiovascular Disease

1 Introduction

Summary and Quick Facts

  • More than 81 million Americans suffer from some form of cardiovascular disease, making it the leading cause of death in the country. As of 2006, cardiovascular disease was responsible for at least one in every 2.9 deaths in the United States.
  • Scientific studies have revealed that several nutrients effectively protect against endothelial dysfunction caused by atherogenic factors. Unlike mainstream medicine’s approach to treating atherosclerosis, which involves addressing only very few proven cardiac risk factors, a comprehensive nutritional regimen can be designed to target all of the risk factors that contribute to atherosclerosis.
  • Comprehensive blood testing helps aging individuals identify and target their specific risk factors, allowing for the development of a personalized, targeted treatment regimen that can be used to preserve and improve cardiovascular health.

Atherosclerosis and cardiovascular disease take a huge toll on our society. More than 81 million Americans suffer from some form of cardiovascular disease, making it the leading cause of death in the country. As of 2006, cardiovascular disease was responsible for at least one in every 2.9 deaths in the United States (American Heart Association: Heart Disease and Stroke Statistics 2010).

Despite the fact that cardiovascular disease is the single most deadly disease in the United States, most individuals, including most mainstream physicians, have a flawed fundamental understanding of the disease. The fact is, long before any symptoms are clinically evident, vascular disease begins as a malfunction of specialized cells that line our arteries. These cells, called endothelial cells, are the key to atherosclerosis and underlying endothelial dysfunction is the central feature of this dreaded disease.

Not every person who suffers from atherosclerosis presents with the risk factors commonly associated with the condition, such as elevated cholesterol, but every single person with atherosclerosis has endothelial dysfunction. Aging humans are faced with an onslaught of atherogenic risk factors that, over time, contribute to endothelial dysfunction and the development of atherosclerosis.

Maturing individuals must address all of the underlying factors that contribute to endothelial dysfunction if they are striving to protect themselves from the ravages of vascular disease. Regrettably, mainstream medicine has failed to identify and correct all of the cardiovascular disease risk factors. This means that people wishing to stave off atherosclerosis must take matters into their own hands to ensure that all underlying causes are effectively neutralized.

In the antiquated view of mainstream medicine, blood vessels have been thought of as stiff pipes that gradually become clogged with excess cholesterol circulating in the bloodstream. The solution that physicians recommend most often is cholesterol-lowering drugs, which target only a very small number of the numerous factors that contribute to cardiovascular disease.

Conventional medicine's preferred method of reestablishing blood flow in clogged vessels is through surgery (coronary artery bypass graft surgery) or by insertion of catheters bearing tiny balloons that crush the plaque deposits against the arterial walls (angioplasty), followed by the implantation of tiny mesh tubes (stents) to keep the blood vessels open. However, the grafts used to reestablish blood flow often develop plaque deposits themselves. The same was true for balloon angioplasty; in their early years, up to half of all angioplasty procedures "failed" when the arteries gradually closed again. Even today, with the use of improved stents, the failure rate is considerable and many people have to undergo repeat angioplasty or even surgery.

Mainstream Medicine Overlooks Proven Alternative to Coronary Stents and Bypass Surgery: Enhanced External Counterpulsation (EECP)

  • Stable coronary artery disease and angina can cause disabling symptoms including shortness of breath, pressure or discomfort in the chest, exercise intolerance, and fatigue.
  • A safe, effective, non-invasive therapy for the symptoms of coronary artery disease and angina is now available. Enhanced external counterpulsation (EECP) alleviates cardiac symptoms by enhancing coronary collateral circulation—alternate pathways by which blood can reach the heart muscle.
  • The procedure is performed in a series of outpatient treatments, in which inflatable cuffs wrapped around the legs inflate and deflate in rhythm with the patient's heartbeat.
  • More than 100 published studies show that EECP can effectively relieve symptoms of heart failure, increase exercise tolerance, reduce reliance on medication, and improve quality of life. Benefits of treatment can last up to five years.
  • This novel therapy simulates the circulatory benefits of exercise, allowing patients to overcome symptoms and resume a healthy, active lifestyle.
  • To learn more about EECP, please review the article titled "Doctors Ignore Proven Alternative to Coronary Stents and Bypass Surgery" in the June 2008 issue of Life Extension Magazine.

2 Endothelial Dysfunction: The Underlying Cause of All Vascular Diseases

The cause and progression of vascular disease is intimately related to the health of the inner arterial wall. Blood vessels are composed of three layers. The outer layer is mostly connective tissue and provides structure to the layers beneath. The middle layer is smooth muscle; it contracts and dilates to control blood flow and maintain blood pressure. The inner lining consists of a thin layer of endothelial cells (the endothelium), which provides a smooth, protective surface. Endothelial cells prevent toxic, blood-borne substances from penetrating the smooth muscle of the blood vessel.

However, as we age, a barrage of atherogenic factors, if left unchecked, damages the delicate endothelial cells. This damage leads to endothelial dysfunction and ultimately allows lipids and toxins to penetrate the endothelial layer and enter the smooth muscle cells. This results in the initiation of an oxidative and inflammatory cascade that culminates in the development of plaque deposits. Subsequently, these plaques begin to calcify and, over time, become prone to rupture. If a plaque deposit ruptures, the result is oftentimes a deadly blood clot.

If people do not take steps to correct the endothelial dysfunction occurring in their aging bodies, the consequence will be a worsening of the epidemic of arterial disease that currently kills 35% of Americans and 30% of all people worldwide (American Heart Association: Heart Disease and Stroke Statistics 2010). Sadly, mainstream medicine continuously fails patients by prescribing drugs that address only a very small number of risk factors that contribute to the pathogenesis of vascular disease.

Numerous factors that directly contribute to endothelial dysfunction have been identified and aging individuals can easily assess their risk for vascular disease through blood testing. The results of these blood tests can then be used to develop targeted intervention strategies to modify levels of risk factors that do not fall within an optimal range. Atherogenic factors that all aging individuals must be aware of include:

  • Elevated LDL cholesterol. LDL is dangerous because it can penetrate the endothelial wall and contribute to the creation foam cells, which form the core of a plaque deposit. Oxidized LDL cholesterol (LDL that has been exposed to free radicals) within the endothelium also triggers an inflammatory process that accelerates vascular disease. Life Extension recommends keeping LDL cholesterol levels below 80 mg/dL.
  • Low HDL cholesterol. HDL protects against vascular disease by transporting cholesterol from the blood vessel wall back to the liver for disposal through a process known as reverse cholesterol transport. If HDL levels are low, then reverse cholesterol transport becomes inefficient, allowing for increased accumulation of cholesterol in the vessel wall. HDL levels of at least 50-60 mg/dL are recommended for optimal vascular protection.
  • Elevated triglycerides. Triglycerides interact with LDL cholesterol to form a particularly dangerous sub-type of LDL known as small-dense LDL. Small-dense LDL particles penetrate the endothelial layer and contribute to plaque formation much more efficiently than larger, more buoyant LDL particles. Life Extension recommends keeping fasting triglycerides below 80 mg/dL to limit the formation of small-dense LDL particles.
  • Oxidized LDL. The oxidation of LDL results in severe vascular damage. Many studies show that oxidized LDL contributes to the entire atherogenic process from start to finish (Matsuura 2008). Levels of oxidized LDL can be assessed via blood testing. Many of the nutrient suggestions in this protocol afford considerable protection against LDL oxidation.
  • Hypertension. High blood pressure is known to aggravate endothelial dysfunction and leading researchers have identified the endothelium as an "end organ" for damage caused by high blood pressure. Life Extension suggests a target optimal blood pressure of 115/75 mmHg (or lower).
  • Elevated C-reactive protein. Inflammation is central to the endothelial dysfunction that underlies vascular disease. An effective way to measure inflammation is through a high-sensitivity C-reactive protein (CRP) blood test. Studies have shown that higher levels of CRP are associated with increased risk of stroke, heart attack, and peripheral vascular disease (Rifai N 2001; Rifai N et al 2001). Stroke patients with the highest CRP levels are two to three times more likely to die or experience a new vascular event within a year than are patients with the lowest levels (Di Napoli M et al 2001).
  • Elevated Lp-PLA2. Like CRP, Lp-PLA2 is a marker of inflammation. However, Lp-PLA2 is a much more specific measure of vascular inflammation than CRP. Lp-PLA2 is an enzyme secreted by inflamed vascular plaque, thus the quantity of it in circulation correlates with the amount of inflamed plaque in the blood vessels. Levels of Lp-PLA2 above 200 ng/mL are indicative of heightened levels of vascular plaque buildup.
  • Elevated omega-6:omega-3 ratio. High levels of pro-inflammatory omega-6 fatty acids relative to anti-inflammatory omega-3 fatty acids create an environment that fosters inflammation and contributes to vascular disease. It has been shown that lowering the omega-6:omega-3 ratio significantly decreases atherosclerotic lesion size and reduces numerous measures of inflammation (Wan, 2010). Life Extension recommends maintaining a blood omega-6:omega-3 ratio of less than 4:1.
  • Elevated glucose. High circulating levels of blood glucose (and insulin) cause microvascular damage that accelerates the atherogenic process, partly by contributing to endothelial dysfunction (Beckman JA et al 2002). It has been shown that a fasting blood glucose level of greater than 85 mg/dL significantly increases risk of cardiovascular related mortality (Bjørnholt, 1999). Life Extension suggests keeping fasting blood glucose levels below 86 mg/dL.
  • Excess insulin. As we age, we lose our ability to utilize insulin to effectively drive blood glucose into energy-producing cells. As glucose levels rise in the blood, the pancreas compensates by producing more insulin. As "insulin resistance" worsens, even more insulin is secreted in attempt to restore glucose control. Excess insulin is associated with a significantly greater risk of heart disease (Bonora, 2007). Life Extension suggests keeping fasting insulin below 5 mcIU/mL.
  • Elevated homocysteine. High homocysteine levels damage endothelial cells and contribute to the initial pathogenesis vascular disease (Riba R et al 2004). Homocysteine levels are associated with risk of heart disease (Haynes WG 2002; Guilland JC et al 2003). To keep homocysteine-induced endothelial damage to a minimum, levels of homocysteine should be kept below 8 µmol/L.
  • Elevated fibrinogen. When a blood clot forms, fibrinogen is converted to fibrin, which forms the structural matrix of a blood clot (Koenig W 1999). Fibrinogen also facilitates platelet adherence to endothelial cells (Massberg S et al 1999). People with high levels of fibrinogen are more than twice as likely to die of a heart attack or stroke as people with normal fibrinogen levels (Wilhelmsen L et al 1984; Packard CJ et al 2000). In a review which included data for over 154,000 patients, every 100 mg/dL increase in fibrinogen levels was associated with a significantly increased risk of developing coronary heart disease, stroke, and with vascular related mortality. In one study, those patients with the lowest one-third fibrinogen levels (mean 236 mg/dL) were much less likely to suffer a stroke, develop cardiovascular disease, or die of other vascular related causes when compared to those with the highest one-third fibrinogen levels (mean 374 mg/dL) (Danesh, 2005). This risk goes up even more in the presence of hypertension (Bots ML et al 2002). Fibrinogen levels should be kept between 295 to 369 mg/dl.
  • Insufficient vitamin D. Vitamin D protects against vascular disease via several different mechanisms, including reducing chronic inflammatory reactions that contribute to the pathology of the disease. It has been shown that low vitamin D levels are associated with increased cardiovascular mortality (Dobnig, 2008). Life Extension suggests maintaining a 25-hydroxy vitamin D blood level of 50 – 80 ng/mL.
  • Insufficient vitamin K. Vitamin K is essential for regulating proteins in the body that direct calcium to the bones and keep it out of the arterial wall. Low vitamin K status predisposes aging humans to vascular calcification (Adams, 2005; Beulens, 2009; Schurgers, 2007), chronic inflammation (Morishita, 2008), and sharply higher heart attack risks (Geleijnse, 2004). Vitamin K blood tests assess levels of vitamin K to maintain healthy coagulation, but at this time are not used to identify optimal levels to reduce heart attack risk. However, there is a substantial amount of evidence that suggests that supplementation with vitamin K (as K1, MK-4 and MK-7) easily corrects the vitamin K deficits that are so common among Americans today (Nouso, 2005; Lin, 2005; Braam, 2004; Berkner, 2004; Gunther, 2004).
  • Low testosterone and excess estrogen (in men). Numerous studies link low testosterone (and excess estradiol) with increased heart attack and stroke risk (Wranicz, 2005; Abbott, 2007; Tivesten, 2006; Dunajska, 2004). Testosterone is intimately involved in the reverse cholesterol transport process, which removes cholesterol from the arterial wall by HDL. Excess estrogen is linked with higher C-reactive protein and a greater propensity for abnormal blood clots to form in arteries, causing a sudden heart attack or stroke (Stork, 2008; Zegura, 2006). Men should keep their free testosterone in a range of 20 – 25 pg/mL and their estradiol levels between 20 – 30 pg/mL (Jankowska, 2009).
  • Insufficient CoQ10. Supplemental CoQ10 alters the pathology of vascular diseases and has the potential for prevention of vascular disease through the inhibition of LDL cholesterol oxidation and by the maintenance of optimal cellular and mitochondrial function throughout the ravages of time and internal and external stresses. The attainment of higher blood levels of CoQ10 (> 3.5 micrograms/mL) with the use of higher doses of CoQ10 appears to enhance both the magnitude and rate of clinical improvement (Langsjoen, 1999).
  • Nitric oxide deficit. Nitric oxide is an important messenger molecule required for healthy cardiovascular function. Nitric oxide enables blood vessels to expand and contract with youthful elasticity and is vital to maintaining the structural integrity of the endothelium, thus protecting against vascular disease. Even when all other risk factors are controlled for, the age-related decline in endothelial nitric oxide too often causes accelerated vascular disease unless corrective measures are taken. Commercial blood tests are not yet available at affordable prices to assess nitric oxide status. Aging individuals should assume they are developing a nitric oxide deficit in their inner arterial wall (the endothelium) and follow simple steps outlined in this protocol to protect themselves (Yavuz, 2004; Cai, 2000; Nitenberg, 2006).

3 Targeting Vascular Disease Risk Factors with Nutritional Therapeutics

Scientific studies have revealed that several nutrients effectively protect against endothelial dysfunction caused by the atherogenic factors identified above. Unlike mainstream medicine's approach to treating atherosclerosis, which involves addressing only very few proven cardiac risk factors, a comprehensive nutritional regimen can be designed to target all of the risk factors that contribute to atherosclerosis.

Omega-3 Fatty Acids

Studies have shown that omega-3 fatty acids combat the development and progression of vascular disease via multiple mechanisms including, lowering triglycerides, lowering blood pressure, improving endothelial function and raising HDL levels (Robinson, 2006).

A team of researchers examined the correlation between tissue omega-3 fatty acid levels and measures of circulating Lp-PLA2, a marker of inflammatory arterial plaque, in over 300 patients. They found a strong, independent and inverse association between tissue omega-3 levels and circulating Lp-PLA2. The researchers went on to conclude that intake of omega-3 fatty acids might reduce Lp-PLA2 levels and reduce the risk of vascular disease (Schmidt, 2008).

In another study involving 563 elderly men, 2.4 grams per day of omega-3 fatty acid supplementation was found to improve arterial elasticity (Hjerkinn, 2006).

In 16 patients with peripheral artery disease who were already being treated with conventional methods, the addition of 2 grams daily of omega-3 fatty acids was shown to significantly improve endothelial function, as measured by brachial artery flow-mediated dilation (from 6.7% to 10.0%) and plasma soluble thrombomodulin (from 33.0 ng/mL to 17.0 ng/mL) (Schiano, 2008). Similarly, another study found that when omega-3 fatty acids were combined with rosuvastatin, the combination improved endothelial dependent vasodilation (-1.42% to 11.36%) while rosuvastatin alone failed to improve endothelial function (Mindrescu, 2008).

Propionyl L-carnitine

Propionyl L-carnitine (PLC) has received attention for its ability to directly improve endothelial function. PLC passes across the mitochondrial membrane to supply L-carnitine directly to the mitochondria, the energy-producing organelles of cells. Carnitines are essential for mitochondrial fatty acid transport and energy production, which is important because endothelial cells and heart muscle cells burn fatty acids for 70 percent of their energy. By contrast, most other cells generate 70 percent of their energy from glucose and only 30 percent from fatty acids (Kaiser KP, 1987).

In human studies, PLC produced significant improvement in maximum walking distance with claudication (sclerotic peripheral vascular disease) and had no major side effects (Wiseman LR et al 1998). Another study found that PLC significantly reduced homocysteine levels when administered intravenously to hemodialysis patients (Signorelli, 2006).

Animal studies suggest PLC may help prevent or decrease the severity of vascular disease. In rabbits fed a high-cholesterol diet, which normally induces endothelial dysfunction and subsequent atherosclerosis, supplementation with PLC resulted in reduced plaque thickness, markedly lower triglyceride levels and reduced proliferation of foam cells (Spagnoli, 1995).

PLC also improves endothelial function by increasing nitric oxide production in animals with normal blood pressure and in animal models of hypertension. Nitric oxide is important because it helps keep arteries open. The increased nitric oxide production induced by PLC is related to its antioxidant properties; PLC reduces reactive oxygen species and increases nitric oxide production in the endothelium in the presence of the antioxidative enzymes superoxide dismutase and catalase (Bueno R et al 2005).

L-arginine

This amino acid has attracted attention for its ability to improve endothelial function. L-arginine serves as the precursor of nitric oxide in the endothelium (Cockcraft JR 2005). To find out whether L-arginine improved arterial function in people with peripheral arterial disease, as well as determine an optimal oral dose, a group of researchers from the University of California, San Francisco, looked at L-arginine's ability to improve walking distance and walking speed among people with peripheral arterial disease. The research group found in a pilot study of 80 patients that 3 g L-arginine daily improved both walking speed and distance (Oka RK et al 2005).

Another study looked at the effects of oral L-arginine in patients with stable coronary artery disease. The team found that L-arginine therapy of 10 g daily improved brachial artery dilation, a measure of endothelial function (Yin WH et al 2005).

Coenzyme Q10

Coenzyme Q10 (CoQ10) CoQ10 is critically important for vascular health, as it is directly involved in the production of ATP, the "energy currency" of the human body. Because the heart is a muscle that never rests, it needs a substantial amount of CoQ10. CoQ10 levels in heart tissue decline disproportionately with age. At age 20, the heart has a higher CoQ10 level than other major organs. At age 80 this is no longer true, with heart levels cut by more than half (Kalen, 1989). CoQ10 pioneer Karl Folkers (1985), in agreement with other Japanese studies, found lower CoQ10 levels in patients with more severe heart disease and showed that CoQ10 supplements significantly raised blood and heart tissue levels of CoQ10 in these patients.

In addition to its involvement in energy production, CoQ10 is also a potent antioxidant. CoQ10 is the first line of defense against LDL oxidation; oxidized LDL is a major contributor to endothelial dysfunction (Thomas, 1995).

CoQ10, in combination with vitamins C, E and selenium, was shown in a randomized controlled trial to significantly improve arterial elasticity in patients with multiple cardiovascular risk factors. The authors found that the antioxidant-induced increases in arterial elasticity were associated with improved glucose and lipid metabolism, as well as decreased blood pressure (Shargorodsky, 2010).

In an animal study, CoQ10 supplementation was shown to improve endothelial function, as measured by thoracic aorta nitric oxide availability and blood pressure (Graham, 2009).

Pomegranate

For HDL to perform its vital functions, an enzyme called paraoxonase-1 (PON-1) is attached to its surface. PON-1 serves to protect HDL from oxidation, which impairs its ability to protect arteries. As humans age, PON-1 levels markedly decline, thereby reducing the ability of HDL to protect against heart attack and stroke. This phenomenon helps explain the onset of accelerated atherosclerosis; where within a period of only a few years, an aging person's healthy arteries rapidly occlude with plaque. In addition to its ability to protect HDL against oxidation, PON-1 has also been shown to hydrolyze (break apart) homocysteine thiolactones, which are responsible for damage to blood vessels. So PON-1, on its own, is a blood vessel protector (Jakubowski, 2001).

Lipid peroxidation is a free radical reaction that severely damages cell membranes and is implicated in a host of degenerative diseases. PON-1 blocks destructive lipid peroxidation reactions, making it a crucial enzyme for aging humans to maintain (Rozenberg, 2003; Leus, 2000; Sapian-Paczkowska, 2010; Ikeda, 2007).

Research indicates that pomegranate and its extracts can significantly elevate levels of PON-1 activity in the body. Pomegranate does this through a number of distinct biomolecular pathways that include combating inflammation and LDL adhesion and favorably modulating gene expression. Pomegranate extracts reduce oxidation and inflammation largely through their effect on PON-1 activity, intervening at each step in the development of atherosclerosis (Aviram, 2000).

Researchers studied the effects of pomegranate on human subjects who consumed pomegranate juice for 2 weeks. The team found dramatic reductions in LDL "clumping" and retention in vessels, accompanied by a 20% increase in PON-1 activity (van Himbergen, 2006).

In atherosclerosis-prone mice supplemented with pomegranate, a 90% reduction in oxidation of LDL cholesterol was seen. Supplemented mice also developed atherosclerotic lesions 44% smaller than controls, an effect attributed to reduction in the number of inflammatory foam cells (van Himbergen, 2006).

Lipoic Acid

This naturally occurring antioxidant serves as a coenzyme in energy metabolism of fats, carbohydrates, and proteins. It can regenerate thioredoxin (an antioxidant protein), vitamin C, and glutathione, which in turn can recycle vitamin E. Lipoic acid also helps manage proper serum glucose levels in diabetic patients (Packer, 2001). In animal studies, it has been shown to reduce endothelial dysfunction (Lee WJ et al 2005a). Human studies have found that lipoic acid improves endothelial function among people with metabolic syndrome (Sola, 2005). Lipoic acid works best in combination with antioxidants including vitamin E, coenzyme Q10, carnitine, and selenomethionine (Mosca, 2002).

Garlic

Aged garlic extract has been studied for its ability to reduce inflammation and the damaging effects of cholesterol in the endothelium (Orekhov,1995). In one study of 15 men with coronary artery disease who were also being treated with statin drugs and low-dose aspirin, two weeks of supplementation with aged garlic extract significantly improved blood flow by improving endothelial function (Williams, 2005).

Finally, high-dose garlic was studied in 152 individuals with clinically observable atherosclerotic plaque buildup. Over 48 months, the study participants experienced significantly less increase in plaque deposits than a control group, and a regression of plaque was seen in some participants, leading researchers to conclude that garlic had a "not only preventative but possibly also a curative role in arteriosclerosis therapy" (Koscielny,1999).

Ginkgo Biloba

Several studies have shown that ginkgo favorable alters endothelial function and reduces levels of oxidized LDL (Kudolo GB et al 2003; Ou, 2009; Pierre, 2008). Ginkgo has also been shown to protect against the formation of foam cells (Tsai, 2010).

In a study involving eight patients who had recently undergone aortocoronary bypass surgery, supplementation with ginkgo biloba extract, 120 mg twice daily, was shown to reduce atherosclerotic plaque formation by 11.9% and reduce nanoplaque size by 24.4%. Furthermore, ginkgo increased levels of endogenous antioxidant enzymes and reduce levels of the dangerous oxidized-LDL (Rodriguez, 2007).

In an animal model, researchers found that ginkgo was effective in reducing high homocysteine-induced intimal thickening, indicating a reversal in the atherosclerotic process (Liu, 2008).

Resveratrol

Experiments have shown that the benefits of resveratrol include improvements in the health of the endothelial tissue lining blood vessels (Balestrieri, 2007; Ungvari, 2007; Wang, 2007; Ballard, 2007). One mechanism by which it does this is to facilitate the generation of endothelial progenitor stem cells, thereby providing the endothelium with fresh new cells.

Resveratrol benefits the circulatory system by eliciting a decrease in the oxidation of low-density lipoprotein (LDL); by fostering decreases in platelet aggregation; and by promoting relaxation of small blood vessels called arterioles (Nissen, 2006; Taylor, 2002; Crouse, 2007; Cloarec, 2007). Collectively, these mechanisms benefit the overall health of the cardiovascular system by decreasing factors that contribute to the development of atherosclerosis, and by decreasing the likelihood of undesirable clotting, which, in turn, decreases the risk of stroke (Opie, 2007). Furthermore, data indicate that resveratrol decreases the incidence of dangerous heart arrhythmias (Chen, 2007).

Quercetin

The so-called French paradox is the phenomenon of low rates of heart disease in a country known for its high intake of fatty foods. Recent research suggests that one of the reasons French people are protected from heart disease is a high intake of quercetin, a potent antioxidant and polyphenol found in red wine (Kuhlman, 2005) and certain vegetables. Numerous studies have examined quercetin and found it to be both a powerful antioxidant and a stimulator of nitric oxide, which inhibits endothelial proliferation, a hallmark of atherosclerosis (Kuhlman, 2005).

In spontaneously hypertensive rats, quercetin, along with other bioflavonoids, preserved endothelial function by increasing nitric oxide and reducing blood pressure (Machha, 2005).

A porcine study showed that quercetin has potent antioxidative properties and protects endothelial cells against induced dysfunction (Reiterer, 2004). Quercetin and resveratrol may work particularly well together.

Green Tea Extract

Green tea extracts, which are rich in natural antioxidants and antiplatelet agents, are routinely used in Asia to lower blood pressure and reduce elevated cholesterol. In studies of smokers, 600 mL green tea (not extract) was shown to decrease markers of inflammation and decrease oxidized cholesterol, both of which are intimately involved in the development of atherosclerosis (Lee W et al 2005b).

A Japanese study of 203 patients found that the more green tea patients drink, the less likely they are to suffer from coronary artery disease (Sano J et al 2004). This study supported an earlier study that found that greater green tea consumption was related to a reduced presence of coronary artery disease in Japanese men (Sasazuki S et al 2000).

Vitamin C (Ascorbic Acid)

Vitamin C inhibits damage caused by oxidative stress. In cigarette smokers, daily supplementation with 500 mg vitamin C significantly decreased the appearance of oxidative stress markers (Dietrich M et al 2002). Another study showed that supplementation with 500 mg vitamin C and 400 IU vitamin E daily reduced the development of accelerated coronary arteriosclerosis following cardiac transplantation (Fang JC et al 2002).

Vitamin C's benefits seem especially profound in people who suffer from both diabetes and coronary artery disease. One study demonstrated that, in this group, vitamin C significantly improved vasodilation (Antoniades C et al 2004).

Vitamin K

Vitamin K is steadily gaining attention for its ability to reduce vascular calcification and help prevent vascular disease (Jie KSG et al 1996). Evidence for the ability of vitamin K to prevent calcification can also be found in an animal study in which researchers administered the anticoagulant warfarin to rats. Warfarin is known to deplete vitamin K. At the end of the study, all the animals had extensive calcification, suggesting they had lost the protective effect of vitamin K (Howe AM 2000).

A large study of more than 4,800 subjects followed for 7-10 years in the Netherlands demonstrated that people in the highest one-third of vitamin K2 intake had a 57% reduction in risk of dying from vascular disease, compared to those with the lowest intake. Furthermore, their risk of having severe aortic calcification plummeted by 52%—a clear demonstration of the vitamin's protective effects (Geleijnse, 2004).

Another study by the same group showed that higher vitamin K2 intake was associated with a 20% decreased risk of coronary artery calcification (Beulens, 2009).

Vitamin E

Vitamin E is often studied in conjunction with vitamin C for its potent antioxidant powers. It has been shown to decrease lipid peroxidation and inhibit smooth muscle cell proliferation, platelet aggregation, monocyte adhesion, oxidized LDL uptake, and cytokine production—all of which occur during sclerotic vascular disease (Munteanu A et al 2004; Harris A et al 2002).

In cultured arterial endothelial cells, vitamin E increased the production of prostacyclin, a potent vasodilator and inhibitor of platelet aggregation (Wu D et al 2004). Most vitamin E supplements come in the form of alpha tocopherol, but it is also important to supplement with around 200 mg of gamma tocopherol to gain vitamin E's comprehensive benefits.

Several studies show that patients with advanced cardiovascular disease exhibit normal plasma levels of alpha tocopherol but have substantially lower levels of gamma tocopherol (Ohrvall, 1996; Kontush, 1999; Ohrvall, 1994). In a seven-year follow-up study of more than 334,000 postmenopausal women with no previous heart disease, greater intake of dietary vitamin E—consisting predominantly of gamma tocopherol—was strongly associated with a lower risk of death from cardiovascular disease. The data did not appear to demonstrate a similarly protective role for supplemental alpha tocopherol (Kushi, 1996).

Numerous animal studies likewise suggest that gamma tocopherol may provide powerful protection for the heart. In laboratory rats, supplementation with gamma tocopherol reduced platelet aggregation and clot formation even more effectively than alpha tocopherol (Saldeen, 1999). In addition, gamma tocopherol at physiological doses was more effective than alpha tocopherol in enhancing the activity of superoxide dismutase (SOD), an antioxidant enzyme that may help reduce the risk of cardiac events (Li, 1999).

Niacin

Niacin reduces VLDL particles. Less VLDL leads to less small-dense LDL (prone to oxidation and atherogenesis) and higher HDL (Carlson, 2005). Niacin also improves endothelial function and nitric oxide synthase activity.

Niacin's benefits are not limited to its influence on blood markers of vascular disease risk. It also reduces heart attack risk dramatically. The Coronary Drug Project was the first to establish that niacin is a powerful agent in lowering heart attack risk. When more than 1,000 heart attack survivors were given 3000 mg of (immediate-release/crystalline) niacin daily for six years, the incidence of recurrent non-fatal heart attacks was reduced by 27%, and the number of strokes was reduced by 26% (Canner, 1986).

Gynostemma pentaphyllum

Gynostemma pentaphyllum (G. pentaphyllum) has long been used in traditional Asian medicine to promote health (Liu 2015). It activates a critical enzyme called adenosine monophosphate-activated protein kinase (AMPK) (Park 2014; Gauhar 2012; Nguyen 2011).

AMPK is found inside every cell (Shirwany 2014). It serves as a master regulating switch, affecting metabolism and longevity (Ulgherait 2014). Levels of activated AMPK decrease with age (Hardman 2014; Yang 2010; Mortensen 2009; Liu 2012; Salminen 2012; Rojas 2011).

Results of G. pentaphyllum-induced AMPK activation include increased fat burning, as well as an increase in cellular glucose uptake (Gauhar 2012; Nguyen 2011). Studies of G. pentaphyllum demonstrate considerable cardiovascular benefits (Circosta 2005; Gou 2016; Tanner 1999; Yu 2016).

A study in people with type II diabetes who were not taking any medications showed daily supplementation with G. pentaphyllum tea for 12 weeks reduced fasting blood sugar, hemoglobin A1C levels, and insulin resistance significantly more than placebo (Huyen 2010). A similar study in people with type II diabetes who were already taking the antidiabetic drug gliclazide showed adding G. pentaphyllum significantly reduced fasting blood sugar more than two-fold, and significantly lowered hemoglobin A1C as well (Huyen 2012). A study in obese individuals showed daily supplementation with G. pentaphyllum extract for 12 weeks significantly reduced body weight, total abdominal fat area, body fat mass, percentage body fat, and body mass index compared with placebo (Park 2014).

Hesperidin

Hesperidin and related flavonoids are found in a variety of plants, but especially in citrus fruits, particularly their peels (Umeno 2016; Devi 2015). Digestion of hesperidin produces a compound called hesperetin along with other metabolites. These compounds are powerful free radical scavengers and have demonstrated anti-inflammatory, insulin-sensitizing, and lipid-lowering activity (Li 2017; Roohbakhsh 2014). Findings from animal and in vitro research suggest hesperidin's positive effects on blood glucose and lipid levels may be related in part to activation of the AMP-activated protein kinase (AMPK) pathway (Jia 2015; Rizza 2011; Zhang 2012). Accumulating evidence suggest hesperidin may help prevent and treat a number of chronic diseases associated with aging (Li 2017).

Hesperidin may protect against diabetes and its complications, partly through activation of the AMPK signaling pathway. Coincidentally, metformin, a leading diabetes medication, also activates the AMPK pathway. In a six-week randomized controlled trial on 24 diabetic participants, supplementation with 500 mg of hesperidin per day improved glycemic control, increased total antioxidant capacity, and reduced oxidative stress and DNA injury (Homayouni 2017). Using urinary hesperetin as a marker of dietary hesperidin, another group of researchers found those with the highest level of hesperidin intake had 32% lower risk of developing diabetes over 4.6 years compared to those with the lowest intake level (Sun 2015).

In a randomized controlled trial, 24 adults with metabolic syndrome were treated with 500 mg of hesperidin per day or placebo for three weeks. After a washout period, the trial was repeated with hesperidin and placebo assignments reversed. Hesperidin treatment improved endothelial function, suggesting this may be one important mechanism behind its benefit to the cardiovascular system. Hesperidin supplementation also led to a 33% reduction in median levels of the inflammatory marker high-sensitivity C-reactive protein (hs-CRP), as well as significant decreases in levels of total cholesterol, apolipoprotein B (apoB), and markers of vascular inflammation, relative to placebo (Rizza 2011). In another randomized controlled trial in overweight adults with evidence of pre-existing vascular dysfunction, 450 mg per day of a hesperidin supplement for six weeks resulted in lower blood pressure and a decrease in markers of vascular inflammation (Salden 2016). Another controlled clinical trial included 75 heart attack patients who were randomly assigned to receive 600 mg hesperidin per day or placebo for four weeks. Those taking hesperidin had significant improvements in levels of high-density lipoprotein (HDL) cholesterol and markers of vascular inflammation and fatty acid and glucose metabolism (Haidari 2015).

Lactobacillus reuteri

Various Lactobacillus species have demonstrated positive effects on risk factors for cardiovascular disease such as cholesterol levels, blood pressure, and markers of inflammation (Upadrasta 2016). A research review found that, of the probiotic strains studied, Lactobacillus reuteri (L. reuteri) NCIMB 30242 had the best evidence for reducing cardiac risk by safely lowering total and LDL cholesterol and levels of inflammatory markers (DiRienzo 2014).

In a randomized controlled trial, 114 participants with high cholesterol levels who were otherwise healthy consumed either a probiotic yogurt providing 2.8 billion colony forming units of microencapsulated L. reuteri NCIMB 30242 or a control yogurt daily for six weeks. The L. reuteri group had reductions in total cholesterol (9%) and LDL-cholesterol (5%), levels relative to the placebo yogurt group. ApoB100 (a structural component of atherogenic LDL and VLDL cholesterol), which at high levels is associated with vascular disease, was significantly reduced in the L. reuteri group (Jones, Martoni, Parent 2012; Semekovich 2016). In another controlled clinical trial on 127 healthy adults with high cholesterol levels, subjects received either capsules of L. reuteri NCIMB 30242 or placebo for nine weeks. Those taking the L. reuteri probiotic had a greater than 9% drop in total cholesterol and a drop in LDL cholesterol levels of over 11.5% compared with placebo. The ratio of apoB-100 to apoA-1 fell by 9% in the L. reuteri-supplemented group compared with placebo. The apoB-100:apoA-1 ratio is a strong predictor of cardiovascular risk, particularly in overweight and obese individuals (Lu 2011; Walldius 2012). High-sensitivity C-reactive protein and fibrinogen, additional markers of cardiovascular risk and inflammation, were also significantly reduced relative to placebo (Jones, Martoni, Prakash 2012). A later analysis of the same study showed vitamin D levels increased more in the L. reuteri group than the placebo group (Jones, Martoni, Prakash 2013). Since low vitamin D levels have been associated with high cardiovascular disease risk (Liu 2016), raising vitamin D levels is another way this probiotic may prevent cardiovascular disease. Interestingly, another post-trial analysis of the data from this study found subjects taking the probiotic also experienced general improvement in functional gastrointestinal symptoms (Jones, Martoni, Ganopolsky 2013).

Centella asiatica

Centella asiatica (C. asiatica) is a perennial herbaceous plant used in traditional Ayurvedic and Chinese medicine for thousands of years (Gohil 2010). The most important bioactive components in C. asiatica are triterpenes, which have been studied extensively for their healing properties, including to the endothelium (Bylka 2014; Incandela, Cesarone 2001; Alqahtani 2015; Zheng 2007; Fong 2015). Centella's benefit to the vascular endothelium appears to be related, at least in part, to anti-inflammatory activity, modulation of collagen formation, and oxidative stress reduction (Belcaro 2011).

C. asiatica has been demonstrated to stabilize atherosclerotic plaques. In two randomized controlled trials in patients with atherosclerosis, supplementation with 60 mg of a triterpenoid extract of C. asiatica, three times daily for 12 months, stabilized atherosclerotic plaques in femoral and carotid arteries (Incandela, Belcaro 2001; Cesarone 2001). A series of studies lasting from 2.5 to 4 years examined the effect of a novel combination of C. asiatica triterpenoid extract and the pine bark extract known as Pycnogenol on progression of mild atherosclerosis. Researchers found the combination reduced and limited the progression of atherosclerotic plaque; they also observed an association between these benefits and a significant reduction in oxidative stress (Belcaro, Dugall 2015; Belcaro 2014; Belcaro, Ippolito 2015).

Pycnogenol

Pycnogenol is a standardized bark extract of the French maritime pine tree (Pinus pinaster). Between two thirds and three quarters of Pycnogenol is made up of procyanidin compounds, specifically catechins and epicatechins (D'Andrea 2010; Rohdewald 2002). Pycnogenol benefits cardiovascular health through a variety of important mechanisms. It has been demonstrated to inhibit inflammation and clotting and to improve endothelial function (Gu 2008).

In a randomized, placebo-controlled, crossover trial, individuals with coronary artery disease received 200 mg Pycnogenol daily for eight weeks followed by placebo or vice versa. Treatment with Pycnogenol resulted in a significant reduction in oxidative stress and a 32% increase in a standardized measure of blood flow and vasodilation, a powerful indicator of endothelial function (Enseleit 2012). In a double-blind placebo-controlled trial in 58 hypertensive adults, those who took 100 mg Pycnogenol daily for 12 weeks reduced their dosage of a calcium-channel blocker and experienced a significant decrease in levels of the powerful vasoconstrictor endothelin-1 (Liu 2004).

In a preclinical study, Pycnogenol suppressed expression of inflammatory and tissue factors involved in the formation of atherosclerotic plaques, including nuclear factor-kappa B, interleukin-6, and interferon-beta (Gu 2008). In a mouse model of induced atherosclerosis, Pycnogenol reduced the size of atherosclerotic plaques; reduced total cholesterol, LDL cholesterol, and triglyceride levels; and raised HDL cholesterol levels (Luo 2015). A clinical trial in smokers found 200 mg Pycnogenol per day for two months, taken before the first cigarette of the day, inhibited smoking-induced platelet aggregation to the level of non-smokers (Araghi-Niknam 2000).

Pycnogenol has been shown, in a preclinical as well as in a randomized clinical trial, to enhance nitric oxide production via increased endothelial nitric oxide synthase activity, which can ameliorate endothelial dysfunction (Fitzpatrick 1998; Nishioka 2007). Enhanced nitric oxide function may also inhibit LDL cholesterol oxidation and platelet aggregation, which are critical steps in atherosclerotic plaque formation (Fitzpatrick 1998).

Citrus Flavonoid Glycoside

Citrus fruits have long been associated with good health, and research has found flavonoid molecules in citrus have powerful cardioprotective and anticancer activity (Turati 2015; Mulvihill 2012; Roohbakhsh 2015; Farooqi 2015; Peterson 2006). Flavonoids are highly concentrated in the peel of citrus fruit (Manthey 1996; Londoño-Londoño 2010; Rawson 2014).

Of particular interest is a unique flavonoid known chemically as hesperetin-7-O-rutinoside 2S. In a clinical absorption trial, hesperetin-7-O-rutinoside 2S was found to be 108% more bioavailable than standard hesperidin (BioActor 2013). Hesperetin-7-O-rutinoside 2S belongs to a special form of flavonoids known as flavonoid glycosides. Laboratory and animal experiments have demonstrated hesperetin-7-O-rutinoside 2S has a beneficial effect on endothelial function and inflammation. In a placebo-controlled crossover trial, 24 participants with metabolic syndrome received 500 mg per day of hesperetin-7-O-rutinoside 2S or placebo for three weeks. A significant improvement in endothelial function was apparent for those in the hesperetin-7-O-rutinoside 2S arm of the trial, and this effect was found even after the supplement had been discontinued. Inflammatory markers were significantly decreased in those taking hesperetin-7-O-rutinoside 2S. This beneficial effect appears to occur as a result of increased expression of endothelial nitric oxide synthase (Possemiers 2015).

4 The Remarkable Lifesaving Benefits of Aspirin

Oftentimes, the benefits of aspirin are overlooked in light of the numerous nutritional ingredients that convey cardio-protective effects. This is unfortunate because maturing individuals can utilize aspirin, along with these nutritional ingredients, to significantly enhance their defense against cardiovascular disease.

Studies indicate that aspirin may protect against heart disease in part by improving endothelial function. In a study involving 41 patients with hypertension and high cholesterol, 100 mg of aspirin daily was shown to lower both systolic and diastolic blood pressure and to increase flow-mediated dilation, a maker of endothelial function (Magen, 2005).
The heart depends on its coronary arteries for the oxygen supply that fuels this most vital of organs. Coronary heart disease occurs when normal blood flow through the arteries that feed the heart is slowed or interrupted by factors such as blood clots or plaque.

Preventing clots is another way that aspirin helps prevent heart attacks. By irreversibly blocking production of clot-promoting compounds known as thromboxanes, aspirin prevents platelets in the blood from latching on to each other and forming a clot. A platelet has a life span of 10 days, and aspirin irreversibly impairs the platelet's clotting ability. Aspirin helps blood flow more smoothly past any plaque that is narrowing an artery, and if a plaque ruptures, aspirin will reduce the likelihood of a clot clinging to it (Steinhubl, 2005).

Aspirin can also help prevent heart disease through its anti-inflammatory action. Inflammation participates in many disease processes in the body, including plaque accumulation in the arteries (Libby, 2002). The growth of plaque can obstruct blood flow through the arteries. If a plaque ruptures due to inflammation, it can trigger a heart attack.

A 2003 meta-analysis examined aspirin's effects on primary heart-attack prevention (that is, the prevention of first heart attacks). In more than 55,000 men and women, aspirin use was associated with a 32% reduction in the risk of having a first heart attack, and with a 15% reduction in the risk of all major vascular events (Eidelman, 2003).

A study presented at the 2005 meeting of the American Heart Association reported on the lifesaving benefits of aspirin therapy. This study examined nearly 9,000 women with stable heart disease, ranging in age from 50 to 79. During more than six years of follow-up, women taking aspirin were 25% less likely to die from heart disease and 17% less likely to die from any cause. Some women took 81 mg of aspirin daily, while others took 325 mg. The study authors stated that the two doses appeared to be similarly effective, but that higher doses of aspirin are associated with a greater risk of certain side effects, such as stomach bleeding (American Heart Association).

A meta-analysis published in 2006 examined the effects of aspirin therapy in preventing cardiovascular events in women and men. Examining data from more than 50,000 women, investigators determined that aspirin therapy was associated with a significant 12% reduction in cardiovascular events in women. Among more than 44,000 men, aspirin therapy produced a significant 14% reduction in all cardiovascular events and an even more impressive 32% reduction in heart attacks (Berger, 2006).

According to the US Preventive Services Task Force, aspirin's proven benefits are reason enough for people to start using it if they have at least a 6% chance of developing coronary heart disease in the next 10 years. By contrast, the American Heart Association recommends aspirin for people whose 10-year risk of developing coronary heart disease is 10% or higher, as long they have no medical contraindications for taking the drug. A doctor can help you calculate your cardiovascular risk based on factors such as tobacco use, cholesterol, and blood pressure. You can also assess your cardiovascular risk by using online risk factor calculators available at the American Heart Association website.

Life Extension strongly recommends that people who have already had a heart attack (or other episode of heart disease) discuss aspirin therapy with their doctor as part of a strategy to prevent future problems. Life Extension also suggests that people with no previous history of cardiovascular disease—but who are nevertheless at high risk for heart disease—strongly consider aspirin therapy in consultation with their personal physician. The recommended dose for preventing heart-related problems is 81-325 mg daily. Speak with your doctor about your personal needs before beginning aspirin therapy.

5 Hormones and Cardiovascular Health

Testosterone and Estrogen Balance (Men)

Recent studies suggest that testosterone-replacement may improve the symptoms of vascular disease. A placebo-controlled crossover study in men with ischemic heart disease and low testosterone levels reported that exercise time and the time to development of ischemic changes on a treadmill test were both increased with testosterone-replacement therapy (Malkin, 2004).

It has been shown that men with lower levels of testosterone have poorer endothelial function. In a study of 187 males, researchers found that those men in the highest quartile of testosterone levels had 1.7 fold greater flow mediated dilation, a marker of endothelial function (Akishita, 2007).

In another study, researchers examined the correlation between testosterone levels and mortality in over 900 men with coronary heart disease. The team found that the mortality rate in patients with testosterone deficiency was 21%, while only 12% of subjects with normal testosterone levels died. The authors of the study concluded that "in patients with coronary disease testosterone deficiency is common and impacts significantly negatively on survival" (Malkin, 2010).

Researchers analyzed 30-day survival data for 126 men who had suffered a heart attack. All of the men who did not survive were found to have low total testosterone levels (<= 300 ng/dL). The team went on to conclude that "a low level of testosterone was independently related to total short-term [post-heart attack] mortality (Militaru, 2010).

Testosterone levels are also inversely associated with the development of coronary artery disease. In a study of men 45 years of age or younger, researchers found that subjects with diagnosed coronary artery disease had significantly lower levels of free testosterone than did healthy, age-matched controls. The researchers went on to caution that, based on their findings, "a low level of free testosterone may be related to the development of premature coronary artery disease" (Turhan, 2007).

Italian researchers compared plasma testosterone levels of 119 elderly men with isolated systolic hypertension to those of 106 nonhypertensive elderly men. All the study participants were 60 to 79 years old, non-obese, nondiabetic, and nonsmokers. The hypertensive men were found to have 14% lower levels of testosterone compared to the nonhypertensive men. In both the hypertensive and nonhypertensive men, low testosterone levels correlated with higher blood pressure values (Fogari, 2003).

In a study of over 11,000 men, followed for up to 10 years, baseline testosterone concentrations were inversely associated with cardiovascular and all-cause mortality. Men with total testosterone levels of 481 ng/dL or greater at baseline were significantly less likely to die of cardiovascular disease or any cause during the follow-up period compared to men with testosterone levels below 481 ng/dL. The correlation held even after adjustment for various other confounding factors. The authors of this study declared that "low testosterone may be a predictive marker for those at high risk of cardiovascular disease" (Khaw, 2007).

A study published in the Journal of the American Medical Association (JAMA) measured blood estradiol (a dominant estrogen) in 501 men with chronic heart failure. Compared to men in the balanced estrogen quintile, men in the lowest estradiol quintile were 317% more likely to die during a 3-year follow-up, while men in the highest estradiol quintile were 133% more likely to die (Jankowska, 2009).

The men in the balanced quintile—with the fewest deaths—had serum estradiol levels between 21.80 and 30.11 pg/mL. This is very similar to the optimal range that Life Extension has long recommended for aging men. The men in the highest quintile who suffered 133% increased death rates had serum estradiol levels of 37.40 pg/mL or above. The lowest estradiol group that suffered a 317% increased death rate had serum estradiol levels under 12.90 pg/mL.

For more information on optimizing male hormone levels in order to prevent not only vascular disease, but many other age-related diseases as well, please review the chapter on Male Hormone Restoration Therapy.

Testosterone Protects Women Too

Testosterone is often thought to be beneficial only for men. However, a study of nearly 3,000 women reveals that maintaining optimal testosterone levels is important for females as well. After assessing testosterone levels at baseline, researchers found that, over a 4.5 year follow-up period, those women with the lowest levels of testosterone were more likely to experience a cardiovascular event and to die of any cause than women with the highest testosterone. The authors concluded "low baseline testosterone in women is associated with increased all-cause mortality and incident cardiovascular events independent of traditional risk factors" (Sievers, 2010).

DHEA (Men and Women)

DHEA is a precursor to sex hormones such as testosterone and estrogen. Levels of steroid hormones, including DHEA, decline with the age-associated onset of a variety of medical conditions, including chronic inflammation, hypertension, and atherosclerosis. Higher levels of DHEA in humans are associated with lower levels of inflammatory biomarkers (Sondergaard HP et al 2004).

A study showed that men with high levels of DHEA tended to have greater protection against aortic atherosclerosis progression (Hak AE et al 2002). Similarly, another study of 419 Japanese individuals found that those with the highest circulating levels of DHEA-sulfate (form of DHEA commonly measured on blood tests) were much less likely to have carotid atherosclerosis (Yoshida, 2010).

Animal studies show a protective role for DHEA in preventing atherosclerosis. Providing DHEA to human vascular endothelial cells in culture increases nitric oxide synthesis, which boosts blood flow (Simoncini T et al 2003).

Progesterone (Women)

Several studies have determined that non-bioidentical progestin promotes the formation of atherosclerosis (Register, 1998; Levine, 1996). The story is quite different for bioidentical progesterone, where multiple animal studies have shown that bioidentical progesterone inhibits the process of atherosclerosis (Morey, 1997; Houser, 2000). To illustrate, scientists fed postmenopausal monkeys a diet which is known to cause atherosclerosis for 30 months. The scientists then divided the monkeys into groups that received estrogen alone, estrogen plus non-bioidentical progestin, or a control group that did not receive hormones. The control group developed substantial atherosclerotic plaque. The administration of estrogen resulted in a 72% decrease in atherosclerotic plaque, compared to the control group. Treatment with non-bioidentical progestin yielded disturbing results. The group that received estrogen combined with non-bioidentical progestin had a similar amount of atherosclerotic plaque as the control group, meaning that non-bioidentical progestin completely reversed estrogen's inhibitory effects on the formation of atherosclerosis (Adams, 1997). In contrast, when the same investigators administered bioidentical progesterone along with estrogen, no such inhibition of estrogen's cardiovascular benefit was seen (Adams, 1990).

In a trial published in the Journal of the American College of Cardiology, researchers studied postmenopausal women with a history of heart attack or coronary artery disease. The women were given estrogen in combination with either bioidentical progesterone or non-bioidentical progestin. After 10 days of treatment the women underwent exercise treadmill tests. Compared to the non-bioidentical progestin group, the amount of time it took to produce myocardial ischemia (reduced blood flow to the heart) on the exercise treadmill was substantially improved in the bioidentical progesterone group (Rosano, 2000).

Estriol (Women)

Growing evidence suggests that estriol may offer benefits to the cardiovascular system. For instance, Japanese scientists found that a group of menopausal women given estriol for 12 months had a significant decrease in both systolic and diastolic blood pressure (Takahashi, 2000). Another study compared the use of estriol for 10 months in 20 postmenopausal and 29 elderly women. Some of the elderly women had decreases in total cholesterol and triglycerides and an increase in beneficial HDL (Nishibe, 1996).

To examine the effects of estriol on atherosclerosis, researchers conducted an experiment in which female rabbits were fed a high cholesterol diet with or without supplemental estriol. The rabbits had their ovaries removed surgically to mimic menopause. Remarkably, the group receiving estriol had 75% less atherosclerosis than the group fed the high cholesterol diet alone (without estriol) (Kano, 2002).

Phytoestrogens (Women)

Following menopause, circulating levels of estrogen are depleted. Phytoestrogens are plant hormones with estrogenic activity. In postmenopausal women, phytoestrogens appear to have estrogen-like benefits such as protection against osteoporosis (Atkinson C et al 2004; Crisafulli A et al 2004a) and possibly hot flashes (Crisafulli A et al 2004b). Phytoestrogens have also been shown to improve vascular function, which tends to decline with age. In one study genistein, a phytoestrogen, provided in a daily 54 mg supplement for one year, significantly improved endothelium-dependent vasodilation in postmenopausal women. Moreover, its benefits were as substantial as those observed in women receiving an estrogen-progestin regimen (Squadrito F et al 2003).

For more information on optimizing female hormone levels in order to prevent not only cardiovascular disease, but other age-related diseases as well, please review the chapter on Female Hormone Restoration Therapy.

6 Summary

Atherosclerosis is a serious threat to the health of a staggering number of individuals across the globe. Its progression has been linked to increased risk of heart attack, stroke, atrial fibrillation and dementia, among other potentially fatal conditions. Since it may begin as early as childhood and aging has been identified as the greatest risk factor for its development, it is vital to combat this disease as early—and as aggressively—as possible. Unfortunately, if aging individuals leave the health of their arteries in the hands of mainstream medicine, they cannot expect conventional approaches to address all the risk factors that lead to atherosclerosis and cardiovascular disease.

Comprehensive blood testing helps aging individuals identify and target their specific risk factors, allowing for the development of a personalized, targeted treatment regimen that can be used to preserve and improve cardiovascular health.

In contrast to the methods of mainstream medicine, which address only very few heart disease risk factors, Life Extension has identified numerous scientifically validated ways by which aging individuals can improve the function of their endothelial cells and greatly reduce their risk of developing deadly atherosclerotic plaque buildup in their blood vessels.

Disclaimer and Safety Information

This information (and any accompanying material) is not intended to replace the attention or advice of a physician or other qualified health care professional. Anyone who wishes to embark on any dietary, drug, exercise, or other lifestyle change intended to prevent or treat a specific disease or condition should first consult with and seek clearance from a physician or other qualified health care professional. Pregnant women in particular should seek the advice of a physician before using any protocol listed on this website. The protocols described on this website are for adults only, unless otherwise specified. Product labels may contain important safety information and the most recent product information provided by the product manufacturers should be carefully reviewed prior to use to verify the dose, administration, and contraindications. National, state, and local laws may vary regarding the use and application of many of the therapies discussed. The reader assumes the risk of any injuries. The authors and publishers, their affiliates and assigns are not liable for any injury and/or damage to persons arising from this protocol and expressly disclaim responsibility for any adverse effects resulting from the use of the information contained herein.

The protocols raise many issues that are subject to change as new data emerge. None of our suggested protocol regimens can guarantee health benefits. Life Extension has not performed independent verification of the data contained in the referenced materials, and expressly disclaims responsibility for any error in the literature.

Abbott RD et al. Serum estradiol and risk of stroke in elderly men. Neurology. 2007 Feb 20;68(8):563-8.

Adams J and Pepping J. Vitamin K in the treatment and prevention of osteoporosis and arterial calcification. Am J Health Syst Pharm. 2005 Aug 1;62(15):1574-81.

Adams MR et al. Inhibition of coronary artery atherosclerosis by 17-beta estradiol in ovariectomized monkeys. Lack of an effect of added progesterone. Arteriosclerosis. 1990 Nov-Dec;10(6):1051-7.

Adams MR et al. Medroxyprogesterone acetate antagonizes inhibitory effects of conjugated equine estrogens on coronary artery atherosclerosis. Arterioscler Thromb Vasc Biol. 1997 Jan;17(1):217-21.

Akishita M et al. Low testosterone level is an independent determinant of endothelial dysfunction in men. Hypertens Res. 2007 Nov;30(11):1029-34.

Alqahtani A, Tongkao-on W, Li KM, Razmovski-Naumovski V, Chan K, Li GQ. Seasonal Variation of Triterpenes and Phenolic Compounds in Australian Centella asiatica (L.) Urb. Phytochemical analysis: PCA.Nov-Dec 2015;26(6):436-443.

American Heart Association. Heart Disease and Stroke Statistics, 2010. Available at: http://www.americanheart.org/downloadable/heart/1265665152970DS-3241%20HeartStrokeUpdate_2010.pdf

American Heart Association; 2005 meeting. Available at http://cme.medscape.com/viewcollection/4739

Antoniades C, Tousoulis D, et al. Vascular endothelium and inflammatory process, in patients with combined Type 2 diabetes mellitus and coronary atherosclerosis: The effects of vitamin C. Diabet Med. 2004 Jun;21(6):552–8.

Araghi-Niknam M, Hosseini S, Larson D, Rohdewald P, Watson RR. Pine bark extract reduces platelet aggregation. Integrative medicine: integrating conventional and alternative medicine.Mar 21 2000;2(2):73-77.

Atkinson C, Compston JE, et al. The effects of phytoestrogen isoflavones on bone density in women: A double-blind, randomized, placebo-controlled trial. Am J Clin Nutr. 2004;79(2):326–33.

Aviram M, Dornfeld L, Rosenblat M, et al. Pomegranate juice consumption reduces oxidative stress, atherogenic modifications to LDL, and platelet aggregation: studies in humans and in atherosclerotic apolipoprotein E-deficient mice. Am J Clin Nutr. 2000 May;71(5):1062-76.

Balestrieri ML, Schiano C, Felice F, et al. Effect of low doses of red wine and pure resveratrol on circulating endothelial progenitor cells. J Biochem (Tokyo). 2007 Nov 4.

Ballard VL, Edelberg JM. Targets for regulating angiogenesis in the ageing endothelium. Expert Opin Ther Targets. 2007 Nov;11(11):1385-99.

Beckman JA, Creager MA, et al. Diabetes and atherosclerosis: Epidemiology, pathophysiology, and management. JAMA. 2002;287(19):2570–81.

Belcaro G, Dugall M, Ippolito E, et al. Pycnogenol(R) and Centella Asiatica for preventing asymptomatic atherosclerosis progression into clinical events. Minerva cardioangiologica.Oct 27 2015.

Belcaro G, Ippolito E, Dugall M, et al. Pycnogenol(R) and Centella asiatica in the management of asymptomatic atherosclerosis progression. Int Angiol. Apr 2015;34(2):150-157.

Belcaro G, Maquart FX, Scoccianti M, et al. TECA (Titrated Extract of Centella Asiatica): new microcirculatory, biomolecular, and vascular application in preventive and clinical medicine. A status paper. Panminerva medica.2011;53(3 Suppl 1):105-118.

Berger JS, Roncaglioni MC, Avanzini F, Pangrazzi I, Tognoni G, Brown DL. Aspirin for the primary prevention of cardiovascular events in women and men: a sex-specific meta-analysis of randomized controlled trials. JAMA. 2006 Jan 18;295(3):306-13.

Berkner KL et al. The physiology of vitamin K nutriture and vitamin K-dependent protein function in atherosclerosis. J Thromb Haemost. 2004 Dec;2(12):2118-32.

Beulens JW et al. High dietary menaquinone intake is associated with reduced coronary calcification. Atherosclerosis. 2009 Apr;203(2):489-93.

BioActor. Cordiart™ formulation has >100% improved bioavailability compared to standard hesperidin. Bioactor B.V; 2013.

Bjørnholt JV et al. Fasting blood glucose: an underestimated risk factor for cardiovascular death. Results from a 22-year follow-up of healthy nondiabetic men. Diabetes Care January 1999 vol. 22 no. 1 45-49.

Bonora E et al. Insulin Resistance as Estimated by Homeostasis Model Assessment Predicts Incident Symptomatic Cardiovascular Disease in Caucasian Subjects From the General Population The Bruneck Study. Diabetes Care February 2007 vol. 30 no. 2 318-324

Bots ML, Elwood PC, et al. Level of fibrinogen and risk of fatal and non-fatal stroke. EUROSTROKE: a collaborative study among research centres in Europe. J Epidemiol Community Health. 2002;56 Suppl 1:i14-18.

Braam LA et al. Beneficial effects of vitamins D and K on the elastic properties of the vessel wall in postmenopausal women: a follow-up study. Thromb Haemost. 2004 Feb;91(2):373-80.

Bueno R, Alvarez de Sotomayor M, et al. L-carnitine and propionyl-L-carnitine improve endothelial dysfunction in spontaneously hypertensive rats: Different participation of NO and COX-products. Life Sci. 2005 Sep 9;77(17):2082–97.

Bylka W, Znajdek-Awizen P, Studzinska-Sroka E, Danczak-Pazdrowska A, Brzezinska M. Centella asiatica in dermatology: an overview. Phytotherapy research: PTR.Aug 2014;28(8):1117-1124.

Cai H and Harrison DG. Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress. Circ Res. 2000 Nov 10;87(10):840-4.

Canner PL, Berge KG, Wenger NK, et al. Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. J Am Coll Cardiol. 1986 Dec; 8(6):1245-55.

Carlson LA et al. Nicotinic acid: the broad-spectrum lipid drug. A 50th anniversary review. J Intern Med. 2005 Aug;258(2):94–114.

Cesarone MR, Belcaro G, Nicolaides AN, et al. Increase in echogenicity of echolucent carotid plaques after treatment with total triterpenic fraction of Centella asiatica: a prospective, placebo-controlled, randomized trial. Angiology.Oct 2001;52 Suppl 2:S19-25.

Chen WP et al. In vitro electrophysiological mechanisms for antiarrhythmic efficacy of resveratrol, a red wine antioxidant. Eur J Pharmacol. 2007 Jan 12;554(2-3):196-204.

Circosta C, De Pasquale R, Occhiuto F. Cardiovascular effects of the aqueous extract of Gynostemma pentaphyllum Makino. Phytomedicine: international journal of phytotherapy and phytopharmacology. Sep 2005;12(9):638-643.

Cloarec M, Caillard P, Provost JC, et al. GliSODin, a vegetal sod with gliadin, as preventative agent vs. atherosclerosis, as confirmed with carotid ultrasound-B imaging. Allerg Immunol.(Paris). 2007 Feb;39(2):45-50.

Cockcraft JR. Exploring vascular benefits of endothelium-derived nitric oxide. Am J Hypertens. 2005 Dec;18(12 Pt 2):177S–83S. Review.

Cohen M. Rosehip - an evidence based herbal medicine for inflammation and arthritis. Australian Family Physician. Jul 2012;41(7):495-498.

Crisafulli A, Altavilla D, et al. Effects of the phytoestrogen genistein on the circulating soluble receptor activator of nuclear factor kappaB ligand-osteoprotegerin system in early postmenopausal women. J Clin Endocrinol Metab. 2004a;89(1):188–92.

Crisafulli A, Marini H, et al. Effects of genistein on hot flushes in early postmenopausal women: A randomized, double-blind EPT- and placebo-controlled study. Menopause. 2004b;11(4):400–4.

Crouse JR, III, Raichlen JS, Riley WA, et al. Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: the METEOR Trial. JAMA. 2007 Mar 28;297(12):1344-53.

D'Andrea G. Pycnogenol: a blend of procyanidins with multifaceted therapeutic applications? Fitoterapia.Oct 2010;81(7):724-736.

Danesh J et al. Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-analysis. JAMA. 2005 Oct 12;294(14):1799-809.

Devi KP, Rajavel T, Nabavi SF, Setzer WN, Ahmadi A, Mansouri K, Nabavi SM. Hesperidin: A promising anticancer agent from nature. Industrial Crops and Products. 2015;76:582-589.

Di Napoli M, Papa F, et al. Prognostic influence of increased C-reactive protein and fibrinogen levels in ischemic stroke. Stroke. 2001;32(1):133–8.

Dietrich M, Block G, et al. Antioxidant supplementation decreases lipid peroxidation biomarker F(2)-isoprostanes in plasma of smokers. Cancer Epidemiol Biomarkers Prev. 2002;11(1):7–13.

DiRienzo DB. Effect of probiotics on biomarkers of cardiovascular disease: implications for heart-healthy diets. Nutrition reviews. Jan 2014;72(1):18-29.

Dobnig H et al. Independent association of low serum 25-hydroxyvitamin d and 1,25-dihydroxyvitamin d levels with all-cause and cardiovascular mortality. Arch Intern Med. 2008 Jun 23;168(12):1340-9.

Dunajska K et al. Evaluation of sex hormone levels and some metabolic factors in men with coronary atherosclerosis. Aging Male. 2004 Sep;7(3):197-204.

Eidelman RS, Hebert PR, Weisman SM, Hennekens CH. An update on aspirin in the primary prevention of cardiovascular disease. Arch Intern Med. 2003 Sep 22;163(17):2006-10.

Enseleit F, Sudano I, Periat D, et al. Effects of Pycnogenol on endothelial function in patients with stable coronary artery disease: a double-blind, randomized, placebo-controlled, cross-over study. European heart journal.Jul 2012;33(13):1589-1597.

Fang JC, Kinlay S, et al. Effect of vitamins C and E on progression of transplant-associated arteriosclerosis: A randomised trial. Lancet. 2002;359(9312):1108–13.

Farooqi AA, Wang Z, Hasnain S, Attar R, Aslam A, Mansoor Q, Ismail M. Citrus fruits and their bioactive ingredients: leading four horsemen from front. Asian Pacific journal of cancer prevention: APJCP.2015;16(6):2575-2580.

Fitzpatrick DF, Bing B, Rohdewald P. Endothelium-dependent vascular effects of Pycnogenol. Journal of cardiovascular pharmacology.Oct 1998;32(4):509-515.

Fogari R, Malacco E, Preti P, et al. Plasma testosterone in isolated systolic hypertension. Hypertension. 2003 Oct;42(4). Epub 2003 Sep 15.

Folkers K, Wolaniuk J, Simonsen R, et al. Biochemical rationale and the cardiac response of patients with muscle disease to therapy with coenzyme Q10. Proc Natl Acad Sci U S A. 1985 Jul;82(13):4513-6.

Fong LY, Ng CT, Zakaria ZA, Baharuldin MT, Arifah AK, Hakim MN, Zuraini A. Asiaticoside Inhibits TNF-alpha-Induced Endothelial Hyperpermeability of Human Aortic Endothelial Cells. Phytotherapy research: PTR.Oct 2015;29(10):1501-1508.

Gauhar R, Hwang SL, Jeong SS, Kim JE, Song H, Park DC, . . . Huh TL. Heat-processed Gynostemma pentaphyllum extract improves obesity in ob/ob mice by activating AMP-activated protein kinase. Biotechnol Lett. Sep 2012;34(9):1607-1616.

Geleijnse JM et al. Dietary intake of menaquinone is associated with a reduced risk of coronary heart disease: the Rotterdam Study. J Nutr. 2004 Nov;134(11):3100-5.

Gohil KJ, Patel JA, Gajjar AK. Pharmacological Review on Centella asiatica: A Potential Herbal Cure-all. Indian Journal of Pharmaceutical Sciences.Sep-Oct 2010;72(5):546-556.

Gou SH, Huang HF, Chen XY, Liu J, He M, Ma YY, . . . Ni JM. Lipid-lowering, hepatoprotective, and atheroprotective effects of the mixture Hong-Qu and gypenosides in hyperlipidemia with NAFLD rats. Journal of the Chinese Medical Association: JCMA. Jan 31 2016.

Graham D et al. Mitochondria-targeted antioxidant MitoQ10 improves endothelial function and attenuates cardiac hypertrophy. Hypertension. 2009 Aug;54(2):322-8.

Gu JQ, Ikuyama S, Wei P, Fan B, Oyama J, Inoguchi T, Nishimura J. Pycnogenol, an extract from French maritime pine, suppresses Toll-like receptor 4-mediated expression of adipose differentiation-related protein in macrophages. American journal of physiology. Endocrinology and metabolism. Dec 2008;295(6):E1390-1400.

Guilland JC, Favier A, et al. [Hyperhomocysteinemia: An independent risk factor or a simple marker of vascular disease? 2. Epidemiological data]. Pathol Biol (Paris). 2003;51(2):111–21.

Gunther KE et al. Low-dose oral vitamin K is safe and effective for outpatient management of patients with an INR>10. Thromb Res. 2004;113(3-4):205-9.

Haidari F, Heybar H, Jalali MT, Ahmadi Engali K, Helli B, Shirbeigi E. Hesperidin supplementation modulates inflammatory responses following myocardial infarction. Journal of the American College of Nutrition. 2015;34(3):205-211.

Hak AE, Witteman JC, et al. Low levels of endogenous androgens increase the risk of atherosclerosis in elderly men: The Rotterdam study. J Clin Endocrinol Metab. 2002;87(8):3632–9.

Hardman SE, Hall DE, Cabrera AJ, Hancock CR, Thomson DM. The effects of age and muscle contraction on AMPK activity and heterotrimer composition. Exp Gerontol. 2014 Jul;55:120-8.

Harris A, Devaraj S, et al. Oxidative stress, alpha-tocopherol therapy, and atherosclerosis. Curr Atheroscler Rep. 2002;4(5):373–80.

Haynes WG. Hyperhomocysteinemia, vascular function and atherosclerosis: Effects of vitamins. Cardiovasc Drugs Ther. 2002;16(5):391–9.

Hjerkinn EM et al. Effect of diet or very long chain omega-3 fatty acids on progression of atherosclerosis, evaluated by carotid plaques, intima-media thickness and by pulse wave propagation in elderly men with hypercholesterolaemia. Eur J Cardiovasc Prev Rehabil. 2006 Jun;13(3):325-33.

Homayouni F, Haidari F, Hedayati M, Zakerkish M, Ahmadi K. Hesperidin Supplementation Alleviates Oxidative DNA Damage and Lipid Peroxidation in Type 2 Diabetes: A Randomized Double-Blind Placebo-Controlled Clinical Trial. Phytotherapy research : PTR. Aug 14 2017.

Houser SL et al. Serum lipids and arterial plaque load are altered independently with high-dose progesterone in hypercholesterolemic male rabbits. Cardiovasc Pathol. 2000 Nov-Dec;9(6):317-22.

Howe AM, Webster WS. Warfarin exposure and calcification of the arterial system in the rat. Int J Exp Pathol. 2000 Feb;81(1):51–6.

Huyen VT, Phan DV, Thang P, Hoa NK, Ostenson CG. Antidiabetic effect of Gynostemma pentaphyllum tea in randomly assigned type 2 diabetic patients. Horm Metab Res. 2010 May;42(5):353-7.

Huyen VT, Phan DV, Thang P, Ky PT, Hoa NK, Ostenson CG. Antidiabetic Effects of Add-On Gynostemma pentaphyllumextract therapy with sulfonylureas in type 2 diabetic patients. Evid Based Complement Alternat Med. 2012;2012:452313.

Ikeda Y, Suehiro T, Itahara T, et al. Human serum paraoxonase concentration predicts cardiovascular mortality in hemodialysis patients. Clin Nephrol. 2007 Jun;67(6):358-65.

Incandela L, Belcaro G, Nicolaides AN, et al. Modification of the echogenicity of femoral plaques after treatment with total triterpenic fraction of Centella asiatica: a prospective, randomized, placebo-controlled trial. Angiology.Oct 2001;52 Suppl 2:S69-73.

Incandela L, Cesarone MR, Cacchio M, et al. Total triterpenic fraction of Centella asiatica in chronic venous insufficiency and in high-perfusion microangiopathy. Angiology.Oct 2001;52 Suppl 2:S9-13.

Jakubowski H, Ambrosius WT, Pratt JH. Genetic determinants of homocysteine thiolactonase activity in humans: implications for atherosclerosis. FEBS Lett. 2001 Feb 23;491(1-2):35-9.

Jankowska EA, Rozentryt P, Ponikowska B. Circulating estradiol and mortality in men with systolic chronic heart failure. JAMA. 2009 May 13;301(18):1892-901.

Jia S, Hu Y, Zhang W, Zhao X, Chen Y, Sun C, . . . Chen K. Hypoglycemic and hypolipidemic effects of neohesperidin derived from Citrus aurantium L. in diabetic KK-A(y) mice. Food Funct. Mar 2015;6(3):878-886.

Jie KSG, et al. Vitamin K status and bone mass in women with and without aortic atherosclerosis: A population based study. Calcif Tiff Int. 1996;59:352–6.

Jones ML, Martoni CJ, Ganopolsky JG, Sulemankhil I, Ghali P, Prakash S. Improvement of gastrointestinal health status in subjects consuming Lactobacillus reuteri NCIMB 30242 capsules: a post-hoc analysis of a randomized controlled trial. Expert Opin Biol Ther. Dec 2013;13(12):1643-1651.

Jones ML, Martoni CJ, Parent M, Prakash S. Cholesterol-lowering efficacy of a microencapsulated bile salt hydrolase-active Lactobacillus reuteri NCIMB 30242 yoghurt formulation in hypercholesterolaemic adults. The British journal of nutrition. May 2012;107(10):1505-1513.

Jones ML, Martoni CJ, Prakash S. Cholesterol lowering and inhibition of sterol absorption by Lactobacillus reuteri NCIMB 30242: a randomized controlled trial. European journal of clinical nutrition. Nov 2012;66(11):1234-1241.

Jones ML, Martoni CJ, Prakash S. Oral supplementation with probiotic L. reuteri NCIMB 30242 increases mean circulating 25-hydroxyvitamin D: a post hoc analysis of a randomized controlled trial. The Journal of clinical endocrinology and metabolism. Jul 2013;98(7):2944-2951.

Kaiser KP, Feinendegen LE. Planar scintigraphy versus PET in measuring fatty acid metabolism of the heart. Herz. 1987 Feb;12(1):41–50.

Kalen A et al. Age-related changes in the lipid compositions of rat and human tissues. Lipids. 1989 Jul;24(7):579-84.

Kano H et al. Estriol retards and stabilizes atherosclerosis through an NO-mediated system. Life Sci. 2002 May 24;71(1):31-42.

Khaw KT et al. Endogenous testosterone and mortality due to all causes, cardiovascular disease, and cancer in men: European prospective investigation into cancer in Norfolk (EPIC-Norfolk) Prospective Population Study. Circulation. 2007 Dec 4;116(23):2694-701.

Koenig W. Fibrinogen and coronary risk. Curr Cardiol Rep. 1999;1(2):112–8.

Kontush A, Spranger T, Reich A, Baum K, Beisiegel U. Lipophilic antioxidants in blood plasma as markers of atherosclerosis: the role of alpha-carotene and gamma-tocopherol. Atherosclerosis. 1999 May;144(1):117-22.

Koscielny J, Klussendorf D, et al. The antiatherosclerotic effect of Allium sativum. Atherosclerosis. 1999 May;144(1):237–49.

Kudolo GB, Wang W, et al. Oral ingestion of Ginkgo biloba extract reduces thiobarbituric acid reacting (TBAR) substances in washed platelets of healthy subjects. J Herb Pharmacother. 2003;3(4):1–15.

Kuhlman DR, Schaefer CA, et al. Quercetin-induced induction of the NO/cGMP pathway depends on Ca2+-activated K+ channel-induced hyperpolarization-mediated Ca2+-entry into cultured human endothelial cells. Planta Med. 2005 Jun;71(6):520–4.

Kushi LH, Folsom AR, Prineas RJ, et al. Dietary antioxidant vitamins and death from coronary heart disease in postmenopausal women. N Engl J Med. 1996 May 2;334(18):1156-62.

Langsjoen PH and LAngsjoen AM. Overview of the use of CoQ10 in cardiovascular disease. Biofactors. 1999;9(2-4):273-84.

Lee W, Min WK, et al. Long-term effects of green tea ingestion on atherosclerotic biological markers in smokers. Clin Biochem. 2005b Jan;38(1):84–7.

Lee WJ, Lee IK, et al. Alpha-lipoic acid prevents endothelial dysfunction in obese rats via activation of AMP-activated protein kinase. Arterioscler Thromb Vasc Biol. 2005a Dec;25(12):2488–94.

Leus FR, Wittekoek ME, Prins J, Kastelein JJ, Voorbij HA. Paraoxonase gene polymorphisms are associated with carotid arterial wall thickness in subjects with familial hypercholesterolemia. Atherosclerosis. 2000 Apr;149(2):371-7.

Levine RL et al. Medroxyprogesterone attenuates estrogen-mediated inhibition of neointima formation after balloon injury of the rat carotid artery. Circulation. 1996 Nov 1;94(9):2221-7.

Li C, Schluesener H. Health-promoting effects of the citrus flavanone hesperidin. Critical reviews in food science and nutrition. Feb 11 2017;57(3):613-631.

Li D, Saldeen T, Romeo F, Mehta JL. Relative effects of alpha- and gamma-tocopherol on low-density lipoprotein oxidation and superoxide dismutase and nitric oxide synthase activity and protein expression in rats. J Cardiovasc Pharmacol Ther. 1999 Oct;4(4):219-26.

Li XL, Wang ZH, Zhao YX, Luo SJ, Zhang DW, Xiao SX, et al. Isolation and antitumor activities of acidic polysaccharide from Gynostemma pentaphyllum Makino. Carbohydr Polym. 2012 Jul 1;89(3):942-7.

Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation. 2002 Mar 5;105(9):1135-43.

Lin C et al. Vitamin K3 triggers human leukemia cell death through hydrogen peroxide generation and histone hyperacetylation. Pharmazie. 2005 Oct;60(10):765-71.

Liu F, Benashski SE, Persky R, Xu Y, Li J, McCullough LD. Age-related changes in AMP-activated protein kinase after stroke. Age (Dordr). 2012;34(1):157-68.

Liu M, Li X, Sun R, Zeng YI, Chen S, Zhang P. Vitamin D nutritional status and the risk for cardiovascular disease. Experimental and therapeutic medicine. Apr 2016;11(4):1189-1193.

Liu X, Wei J, Tan F, Zhou S, Wurthwein G, Rohdewald P. Pycnogenol, French maritime pine bark extract, improves endothelial function of hypertensive patients. Life sciences.Jan 2 2004;74(7):855-862.

Liu Y, Wang Z, Zhang J. Dietary Chinese Herbs: Chemistry, Pharmacology and Clinical Evidence. Springer Vienna; 2015.Li XL, Wang ZH, Zhao YX, Luo SJ, Zhang DW, Xiao SX, et al. Isolation and antitumor activities of acidic polysaccharide from Gynostemma pentaphyllum Makino. Carbohydr Polym. 2012 Jul 1;89(3):942-7.

Liu F, Benashski SE, Persky R, Xu Y, Li J, McCullough LD. Age-related changes in AMP-activated protein kinase after stroke. Age (Dordr). 2012;34(1):157-68.

Liu F et al. Inhibitory effect of Ginkgo biloba extract on hyperhomocysteinemia-induced intimal thickening in rabbit abdominal aorta after balloon injury. Phytother Res. 2008 Apr;22(4):506-10.

Liu Y, Wang Z, Zhang J. Dietary Chinese Herbs: Chemistry, Pharmacology and Clinical Evidence. Springer Vienna; 2015.

Londoño-Londoño J, Lima VRd, Lara O, Gil A, Pasa TBC, Arango GJ, Pineda JRR. Clean recovery of antioxidant flavonoids from citrus peel: Optimizing an aqueous ultrasound-assisted extraction method. Food chemistry.3/1/ 2010;119(1):81-87.

Lu M, Lu Q, Zhang Y, Tian G. ApoB/apoA1 is an effective predictor of coronary heart disease risk in overweight and obesity. Journal of biomedical research. 2011;25(4):266-273.

Luo H, Wang J, Qiao C, Ma N, Liu D, Zhang W. Pycnogenol attenuates atherosclerosis by regulating lipid metabolism through the TLR4-NF-kappaB pathway. Experimental & molecular medicine.2015;47:e191.

Machha A, Mustafa MR. Chronic treatment with flavonoids prevents endothelial dysfunction in spontaneously hypertensive rat aorta. J Cardiovasc Pharmacol. 2005 Jul;46(1):36–40.

Magen E et al. Effects of low-dose aspirin on blood pressure and endothelial function of treated hypertensive hypercholesterolaemic subjects. J Hum Hypertens. 2005 Sep;19(9):667-73.

Malkin CJ et al. Low serum testosterone and increased mortality in men with coronary heart disease. Heart. 2010 Nov;96(22):1821-5.

Malkin CJ, Pugh PJ, Morris PD, et al. Testosterone replacement in hypogonadal men with angina improves ischaemic threshold and quality of life. Heart. 2004 Aug;90(8):871-6.

Manthey JA, Grohmann K. Concentrations of Hesperidin and Other Orange Peel Flavonoids in Citrus Processing Byproducts. Journal of agricultural and food chemistry.1996;44(3):811-814.

Martoni CJ, Labbe A, Ganopolsky JG, Prakash S, Jones ML. Changes in bile acids, FGF-19 and sterol absorption in response to bile salt hydrolase active L. reuteri NCIMB 30242. Gut Microbes. 2015;6(1):57-65.

Massberg S, Enders G, et al. Fibrinogen deposition at the postischemic vessel wall promotes platelet adhesion during ischemia-reperfusion in vivo. Blood. 1999;94(11):3829–38.

Matsuura E et al. Oxidation of LDL and its clinical implication. Autoimmun Rev. 2008 Jul;7(7):558-66.

Militaru C et al. Serum testosterone and short-term mortality in men with acute myocardial infarction. Cardiol J. 2010;17(3):249-53.

Miller M, Dobs A, Yuan Z, Battisti WP, Palmisano J. The effect of simvastatin on triglyceride-rich lipoproteins in patients with type 2 diabetic dyslipidemia: a SILHOUETTE trial sub-study. Curr Med Res Opin. 2006 Feb;22(2):343-50.

Mindrescu C et al. Omega-3 fatty acids plus rosuvastatin improves endothelial function in South Asians with dyslipidemia. Vasc Health Risk Manag. 2008;4(6):1439-47.

Morey AK et al. Estrogen and progesterone inhibit vascular smooth muscle proliferation. Endocrinology. 1997 Aug;138(8):3330-9.

Morishita M et al. Osteoclast inhibitory effects of vitamin K2 alone or in combination with etidronate or risedronate in patients with rheumatoid arthritis: 2-year results. J Rheumatol. 2008 Mar;35(3):407-13.

Mortensen B, Poulsen P, Wegner L, et al. Genetic and metabolic effects on skeletal muscle AMPK in young and older twins. Am J Physiol Endocrinol Metab. 2009;297:E956–E64.

Mosca L, Marcellini S, et al. Modulation of apoptosis and improved redox metabolism with the use of a new antioxidant formula. Biochem Pharmacol. 2002;63(7):1305–14.

Mulvihill EE, Huff MW. Citrus flavonoids and the prevention of atherosclerosis. Cardiovascular & hematological disorders drug targets.Dec 2012;12(2):84-91.

Munteanu A, Zingg JM, et al. Anti-atherosclerotic effects of vitamin E—myth or reality? J Cell Mol Med. 2004;8(1):59–76.

Nguyen PH, Gauhar R, Hwang SL, et al. New dammarane-type glucosides as potential activators of AMP-activated protein kinase (AMPK) from Gynostemma pentaphyllum. Bioorg Med Chem. 2011 Nov 1;19(21):6254-60.

Ninomiya K, Matsuda H, Kubo M, Morikawa T, Nishida N, Yoshikawa M. Potent anti-obese principle from Rosa canina: structural requirements and mode of action of trans-tiliroside. Bioorg Med Chem Lett. 2007 Jun 1;17(11):3059-64.

Nishibe A et al. [Effect of estriol and bone mineral density of lumbar vertebrae in elderly and postmenopausal women]. Nippon Ronen Igakkai Zasshi. 1996 May;33(5):353-9.

Nishioka K, Hidaka T, Nakamura S, et al. Pycnogenol, French maritime pine bark extract, augments endothelium-dependent vasodilation in humans. Hypertension research: official journal of the Japanese Society of Hypertension.Sep 2007;30(9):775-780.

Nissen SE, Nicholls SJ, Sipahi I, et al. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA. 2006 Apr 5;295(13):1556-65.

Nitenberg A. [Hypertension, endothelial dysfunction and cardiovascular risk] Arch Mal Coeur Vaiss. 2006 Oct;99(10):915-21.

Nouso K et al. Regression of hepatocellular carcinoma during vitamin K administration. World J Gastroenterol. 2005 Nov 14;11(42):6722-4.

Ohrvall M, Sundlof G, Vessby B. Gamma, but not alpha, tocopherol levels in serum are reduced in coronary heart disease patients. J Intern Med. 1996 Feb;239(2):111-7.

Ohrvall M, Tengblad S, Vessby B. Tocopherol concentrations in adipose tissue. Relationships of tocopherol concentrations and fatty acid composition in serum in a reference population of Swedish men and women. Eur J Clin Nutr. 1994 Mar;48(3):212-8.

Oka RK, Szuba A, Giacomini JC, et al. A pilot study of L-arginine supplementation on functional capacity in peripheral artery disease. Vasc Med. 2005 Nov;10(4):265-74.

Opie LH and Lecour S. The red wine hypothesis: from concepts to protective signalling molecules. Eur Heart J. 2007 Jul;28(14):1683-93.

Orekhov AN, Tertov VV, et al. Direct anti-atherosclerosis-related effects of garlic. Ann Med. 1995 Feb;27(1):63–5.

Ou HC et al. Ginkgo biloba extract attenuates oxLDL-induced oxidative functional damages in endothelial cells. J Appl Physiol. 2009 May;106(5):1674-85.

Packard CJ, O'Reilly DS, et al. Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. West of Scotland Coronary Prevention Study Group. N Engl J Med. 2000;343(16):1148–55.

Packer L, Kraemer K, et al. Molecular aspects of lipoic acid in the prevention of diabetes complications. Nutrition. 2001;17(10):888–95.

Park SH, Huh TL, Kim SY, et al. Antiobesity effect of Gynostemma pentaphyllum extract (actiponin): a randomized, double-blind, placebo-controlled trial. Obesity (Silver Spring). 2014 Jan;22(1):63-71.

Peterson JJ, Dwyer JT, Beecher GR, Bhagwat SA, Gebhardt SE, Haytowitz DB, Holden JM. Flavanones in oranges, tangerines (mandarins), tangors, and tangelos: a compilation and review of the data from the analytical literature. Journal of Food Composition and Analysis.2006;19:S66-S73.

Pierre SV et al. The standardized Ginkgo biloba extract Egb-761 protects vascular endothelium exposed to oxidized low density lipoproteins. Cell Mol Biol (Noisy-le-grand). 2008 Oct 26;54 Suppl:OL1032-42.

Possemiers S. A novel polyphenol extract improves endothelial function and bioavailability: An extract from sweet orange. Agro Food Industry Hi Tech.July/August 2015 2015;26(4):6-10.

Rawson NE, Ho C-T, Li S. Efficacious anti-cancer property of flavonoids from citrus peels. Food Science and Human Wellness.2014;3(3–4):104-109.

Register TC et al. Conjugated equine estrogens alone, but not in combination with medroxyprogesterone acetate, inhibit aortic connective tissue remodeling after plasma lipid lowering in female monkeys. Arterioscler Thromb Vasc Biol. 1998 Jul;18(7):1164-71.

Reiterer G, Toborek M, et al. Quercetin protects against linoleic acid-induced porcine endothelial cell dysfunction. J Nutr. 2004 Apr;134(4):771–5.

Riba R, Nicolaou A, et al. Altered platelet reactivity in peripheral vascular disease complicated with elevated plasma homocysteine levels. Atherosclerosis. 2004;175(1):69–75.

Rifai N, Ridker PM. High-sensitivity C-reactive protein: A novel and promising marker of coronary heart disease. Clin Chem. 2001;47(3):403–11.

Rifai N. C-reactive protein and coronary heart disease: Diagnostic and therapeutic implications for primary prevention. Cardiovasc Toxicol. 2001;1(2):153–7.

Rizza S, Muniyappa R, Iantorno M, Kim JA, Chen H, Pullikotil P, . . . Quon MJ. Citrus polyphenol hesperidin stimulates production of nitric oxide in endothelial cells while improving endothelial function and reducing inflammatory markers in patients with metabolic syndrome. The Journal of clinical endocrinology and metabolism. May 2011;96(5):E782-792.

Robinson JG and Stone NJ. Antiatherosclerotic and antithrombotic effects of omega-3 fatty acids. Am J Cardiol. 2006 Aug 21;98(4A):39i-49i.

Rodriguez et al. Reduction of atherosclerotic nanoplaque formation and size by Ginkgo biloba (EGb 761) in cardiovascular high-risk patients. Atherosclerosis. 2007 Jun;192(2):438-44.

Rohdewald P. A review of the French maritime pine bark extract (Pycnogenol), a herbal medication with a diverse clinical pharmacology. International journal of clinical pharmacology and therapeutics.Apr 2002;40(4):158-168.

Rojas J, Arraiz N, Aguirre M, et al. AMPK as Target for Intervention in Childhood and Adolescent Obesity. Journal of Obesity. 2011;2011:252817. 

Roohbakhsh A, Parhiz H, Soltani F, Rezaee R, Iranshahi M. Molecular mechanisms behind the biological effects of hesperidin and hesperetin for the prevention of cancer and cardiovascular diseases. Life sciences.Mar 1 2015;124:64-74.

Roohbakhsh A, Parhiz H, Soltani F, Rezaee R, Iranshahi M. Neuropharmacological properties and pharmacokinetics of the citrus flavonoids hesperidin and hesperetin--a mini-review. Life sciences. Sep 15 2014;113(1-2):1-6.

Rosano GM et al. Natural progesterone, but not medroxyprogesterone acetate, enhances the beneficial effect of estrogen on exercise-induced myocardial ischemia in postmenopausal women. J Am Coll Cardiol. 2000 Dec;36(7):2154-9.

Rozenberg O, Rosenblat M, Coleman R, Shih DM, Aviram M. Paraoxonase (PON-1) deficiency is associated with increased macrophage oxidative stress: studies in PON-1-knockout mice. Free Radic Biol Med. 2003 Mar 15;34(6):774-84.

Saldeen T, Li D, Mehta JL. Differential effects of alpha- and gamma-tocopherol on low-density lipoprotein oxidation, superoxide activity, platelet aggregation and arterial thrombogenesis. J Am Coll Cardiol. 1999 Oct;34(4):1208-15.

Salden BN, Troost FJ, de Groot E, Stevens YR, Garces-Rimon M, Possemiers S, . . . Masclee AA. Randomized clinical trial on the efficacy of hesperidin 2S on validated cardiovascular biomarkers in healthy overweight individuals. The American journal of clinical nutrition. Dec 2016;104(6):1523-1533.

Salminen A, Kaarniranta K. AMP-activated protein kinase (AMPK) controls the aging process via an integrated signaling network. Ageing Res Rev. 2012 Apr;11(2):230-41.

Sano J, Inami S, et al. Effects of green tea intake on the development of coronary artery disease. Circ J. 2004 Jul;68(7):665–70.

Sapian-Raczkowska B, Rabczyński M, Adamiec R. [Paraoxonase—important enzyme of the lipid metabolism and potential ally in the antiatherosclerotic treatment]. Pol Merkur Lekarski. 2010;29(173):325-7. [Article in Polish]

Sasazuki S, Kodama H, et al. Relation between green tea consumption and the severity of coronary atherosclerosis among Japanese men and women. Ann Epidemiol. 2000 Aug;10(6):401–8.

Schiano V et al. Omega-3 polyunsaturated fatty acid in peripheral arterial disease: effect on lipid pattern, disease severity, inflammation profile, and endothelial function. Clin Nutr. 2008 Apr;27(2):241-7.

Schmidt EB et al. Lipoprotein-associated phospholipase A2 concentrations in plasma are associated with the extent of coronary artery disease and correlate to adipose tissue levels of marine n-3 fatty acids. Atherosclerosis. 2008 Jan;196(1):420-4.

Schurgers LJ, Spronk HM, Soute BA, et al. Regression of warfarin-induced medial elastocalcinosis by high intake of vitamin K in rats. Blood. 2007 Apr;109(7):2823-31.

Semekovich CF, Goldman L. (ed.). Goldman-Cecil Medicine. Twenty-Fifth edition. Chapter 206: Disorders of Lipid Metabolism; 1389-1397.e3. Copyright 2016 Saunders, an imprint of Elsevier Inc. www.clinicalkey.com. Accessed 7/7/2016.

Shargorodsky M et al. Effect of long-term treatment with antioxidants (vitamin C, vitamin E, coenzyme Q10 and selenium) on arterial compliance, humoral factors and inflammatory markers in patients with multiple cardiovascular risk factors. Nutr Metab (Lond). 2010 Jul 6;7:55.

Shirwany NA, Zou MH. AMPK: A cellular metabolic and redox sensor. A minireview. Frontiers in bioscience (Landmark edition). 2014;19:447-474.

Sievers C et al. Low testosterone levels predict all-cause mortality and cardiovascular events in women: a prospective cohort study in German primary care patients.

Signorelli SS et al. Propionyl-L-carnitine therapy: effects on endothelin-1 and homocysteine levels in patients with peripheral arterial disease and end-stage renal disease. Kidney Blood Press Res. 2006;29(2):100-7.

Simoncini T, Mannella P, et al. Dehydroepiandrosterone modulates endothelial nitric oxide synthesis via direct genomic and nongenomic mechanisms. Endocrinology. 2003;144(8):3449–55.

Sola S, Mir MQ, et al. Irbesartan and lipoic acid improve endothelial function and reduce markers of inflammation in the metabolic syndrome: Results of the Irbesartan and Lipoic Acid in Endothelial Dysfunction (ISLAND) study. Circulation. 2005 Jan 25;111(3):343–8.

Sondergaard HP, Hansson LO, et al. The inflammatory markers C-reactive protein and serum amyloid A in refugees with and without posttraumatic stress disorder. Clin Chim Acta. 2004;342(1-2):93–8.

Spagnoli LG, Orlandi A, et al. Propionyl-L-carnitine prevents the progression of atherosclerotic lesions in aged hyperlipemic rabbits. Atherosclerosis. 1995 Apr 7;114(1):29–44.

Squadrito F, Altavilla D, et al. Effect of genistein on endothelial function in postmenopausal women: A randomized, double-blind, controlled study. Am J Med. 2003;114(6):470–6.

Steinhubl SR, Moliterno DJ. The role of the platelet in the pathogenesis of athero-thrombosis. Am J Cardiovasc Drugs. 2005;5(6):399-408.

Stork S et al. Endogenous sex hormones and C-reactive protein in healthy postmenopausal women. J Intern Med. 2008 Sep;264(3):245-53.

Sun Q, Wedick NM, Tworoger SS, Pan A, Townsend MK, Cassidy A, . . . van Dam RM. Urinary Excretion of Select Dietary Polyphenol Metabolites Is Associated with a Lower Risk of Type 2 Diabetes in Proximate but Not Remote Follow-Up in a Prospective Investigation in 2 Cohorts of US Women. The Journal of nutrition. Jun 2015;145(6):1280-1288.

Takahashi K et al. Safety and efficacy of oestriol for symptoms of natural or surgically induced menopause. Hum Reprod. 2000 May;15(5):1028-36.

Tanner MA, Bu X, Steimle JA, Myers PR. The direct release of nitric oxide by gypenosides derived from the herb Gynostemma pentaphyllum. Nitric Oxide. Oct 1999;3(5):359-365.

Taylor AJ, Kent SM, Flaherty PJ, Coyle LC, Markwood TT, Vernalis MN. ARBITER: Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol: a randomized trial comparing the effects of atorvastatin and pravastatin on carotid intima medial thickness. Circulation. 2002 Oct 15;106(16):2055-60.

Thomas SR et al. Coantioxidants make alpha-tocopherol an efficient antioxidant for low-density lipoprotein. Am J Clin Nutr. 1995 Dec;62(6 Suppl):1357S-1364S.

Tivesten A et al. Circulating estradiol is an independent predictor of progression of carotid artery intima-media thickness in middle-aged men. J Clin Endocrinol Metab. 2006 Nov;91(11):4433-7.

Tsai JY et al. EGb761 ameliorates the formation of foam cells by regulating the expression of SR-A and ABCA1: role of haem oxygenase-1. Cardiovasc Res. 2010 Dec 1;88(3):415-23.

Turati F, Rossi M, Pelucchi C, Levi F, La Vecchia C. Fruit and vegetables and cancer risk: a review of southern European studies. The British journal of nutrition.Apr 2015;113 Suppl 2:S102-110.

Turhan S et al. The association between androgen levels and premature coronary artery disease in men. Coron Artery Dis. 2007 May;18(3):159-62.

Ulgherait M, Rana A, Rera M, et al. AMPK modulates tissue and organismal aging in a cell-non-autonomous manner. Cell reports. 2014;8(6):1767-1780.

Umeno A, Horie M, Murotomi K, Nakajima Y, Yoshida Y. Antioxidative and Antidiabetic Effects of Natural Polyphenols and Isoflavones. Molecules. May 30 2016;21(6).

Ungvari Z, Orosz Z, Rivera A, et al. Resveratrol increases vascular oxidative stress resistance. Am J Physiol Heart Circ Physiol. 2007 May;292(5):H2417-24.

Upadrasta A, Madempudi RS. Probiotics and blood pressure: current insights. Integrated blood pressure control. 2016;9:33-42.

van Himbergen TM, van Tits LJ, Roest M, Stalenhoef AF. The story of PON-1: how an organophosphate-hydrolysing enzyme is becoming a player in cardiovascular medicine. Neth J Med. 2006 Feb;64(2):34-8.

Walldius G, Frank S and Kostner G (eds.). Biochemistry, Genetics and Molecular Biology. Chapter 5: The apoB/apoA-I Ratio is a Strong Predictor of Cardiovascular Risk. http://www.intechopen.com/books/lipoproteins-role-in-health-and-diseases/the-apob-apoa-i-ratio-is-a-strong-predictor-of-cardiovascular-risk. 10/3/2012. Accessed 7/7/2016.

Wan JB et al. Endogenously Decreasing Tissue n-6/n-3 Fatty Acid Ratio Reduces Atherosclerotic Lesions in Apolipoprotein E-Deficient Mice by Inhibiting Systemic and Vascular Inflammation. Arterioscler Thromb Vasc Biol. 2010 Aug 12.

Wang XB, Huang J, Zou JG, et al. Effects of resveratrol on number and activity of endothelial progenitor cells from human peripheral blood. Clin Exp Pharmacol Physiol. 2007 Nov;34(11):1109-15.

Wilhelmsen L, Svardsudd K, et al. Fibrinogen as a risk factor for stroke and myocardial infarction. N Engl J Med. 1984;311(8):501–5.

Williams MJ, Sutherland WH, et al. Aged garlic extract improves endothelial function in men with coronary artery disease. Phytother Res. 2005 Apr;19(4):314–9.

Wiseman LR, Brogden RN. Propionyl-L-carnitine. Drugs Aging. 1998 Mar;12(3):243–8; discussion 249–50.

Wranicz JK et al. The relationship between sex hormones and lipid profile in men with coronary artery disease. Int J Cardiol. 2005 May 11;101(1):105-10.

Wu D, Liu L, Meydani M, et al. Effect of vitamin E on prostacyclin (PGI2) and prostaglandin (PG) E2 production by human aorta endothelial cells: mechanism of action. Ann N Y Acad Sci. 2004 Dec;1031:425-7.

Yang Z, Kahn BB, Shi H, Xue BZ. Macrophage alpha1 AMP-activated protein kinase (alpha1AMPK) antagonizes fatty acid-induced inflammation through SIRT1. J Biol Chem. 2010 Jun 18;285(25):19051-9.

Yavuz BB et al. Advanced age is associated with endothelial dysfunction in healthy elderly subjects. Gerontology. 2008;54(3):153-6.

Yin WH, Chen JW, et al. L-arginine improves endothelial function and reduces LDL oxidation in patients with stable coronary artery disease. Clin Nutr. 2005 Dec;24(6):988–97.

Yoshida S et al. Dehydroepiandrosterone sulfate is inversely associated with sex-dependent diverse carotid atherosclerosis regardless of endothelial function. Atherosclerosis. 2010 Sep;212(1):310-5.

Yu H, Guan Q, Guo L, Zhang H, Pang X, Cheng Y, . . . Sun Y. Gypenosides alleviate myocardial ischemia-reperfusion injury via attenuation of oxidative stress and preservation of mitochondrial function in rat heart. Cell Stress & Chaperones. Jan 22 2016.

Zegura B et al. The effect of various menopausal hormone therapies on markers of inflammation, coagulation, fibrinolysis, lipids, and lipoproteins in healthy postmenopausal women. Menopause. 2006 Jul-Aug;13(4):643-50.

Zhang J, Sun C, Yan Y, Chen Q, Luo F, Zhu X, . . . Chen K. Purification of naringin and neohesperidin from Huyou (Citrus changshanensis) fruit and their effects on glucose consumption in human HepG2 cells. Food chemistry. Dec 01 2012;135(3):1471-1478.

Zheng CJ, Qin LP. Chemical components of Centella asiatica and their bioactivities. Zhong xi yi jie he xue bao = Journal of Chinese integrative medicine. May 2007;5(3):348-351.